Longboard Pharma saw significant growth after the initial spike, with potential catalysts in the future. LBPH develops neurological medicines, with a strong pedigree from Arena Pharmaceuticals. Lead ...
Longboard Pharmaceuticals has seen a significant increase in its stock price following positive data from its Phase 1b/2a study of bexicaserin, a treatment for developmental and epileptic ...
Initiated Single-Ascending Dose (SAD) Phase 1 clinical study evaluating LP659 LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical ...
Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data for ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results